Format

Send to

Choose Destination
Ann Rheum Dis. 2017 Jan;76(1):270-276. doi: 10.1136/annrheumdis-2016-209768. Epub 2016 Sep 12.

The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index.

Author information

1
Rheumatology Section, Department of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy.
2
Department of Rheumatology, Basel University, Basel, Switzerland.
3
Division of Rheumatology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
4
Department of Rheumatology, 12 de Octubre University Hospital, Madrid, Spain.
5
Department of Rheumatology and Immunology, University of Pécs, Medical Centre, Pécs, Hungary.
6
Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, Royal Free Campus, University College London, London, UK.
7
Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.
8
Internal Medicine Department, Claude Huriez Hospital, Lille University, Lille, France.
9
NIHR Manchester Musculoskeletal Biomedical Research Unit, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
10
Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.
11
Department of Medicine, St. Joseph's Health Care, University of Western Ontario, London, Ontario, Canada.
12
Department of Rheumatology and Clinical Immunology, Justus-Liebig University Giessen, Bad Neuheim, Germany.
13
Clinic for Rheumatology, University of Lübeck, Lübeck, Germany.
14
Department of Rheumatology and Clinical Immunology, University Hospital Charité, Berlin, Germany.
15
Rheumatology A Department, INSERM U1016 UMR8104, Cochin Hospital, Paris Descartes University, Paris, France.

Abstract

BACKGROUND:

Validity of European Scleroderma Study Group (EScSG) activity indexes currently used to assess disease activity in systemic sclerosis (SSc) has been criticised.

METHODS:

Three investigators assigned an activity score on a 0-10 scale for 97 clinical charts. The median score served as gold standard. Two other investigators labelled the disease as inactive/moderately active or active/very active. Univariate-multivariate linear regression analyses were used to define variables predicting the 'gold standard', their weight and derive an activity index. The cut-off point of the index best separating active/very active from inactive/moderately active disease was identified by a receiver-operating curve analysis. The index was validated on a second set of 60 charts assessed by three different investigators on a 0-10 scale and defined as inactive/moderately active or active/very active by other two investigators. One hundred and twenty-three were investigated for changes over time in the index and their relationships with those in the summed Medsger severity score (MSS).

RESULTS:

A weighted 10-point activity index was identified and validated: Δ-skin=1.5 (Δ=patient assessed worsening during the previous month), modified Rodnan skin score (mRss) >18=1.5, digital ulcers=1.5, tendon friction rubs=2.25, C-reactive protein >1 mg/dL=2.25 and diffusing capacity of the lung for CO (DLCO) % predicted <70%=1.0. A cut-off ≥2.5 was found to identify patients with active disease. Changes in the index paralleled those of MSS (p=0.0001).

CONCLUSIONS:

A preliminarily revised SSc activity index has been developed and validated, providing a valuable tool for clinical practice and observational studies.

KEYWORDS:

Autoimmune Diseases; Disease Activity; Systemic Sclerosis

PMID:
27621285
DOI:
10.1136/annrheumdis-2016-209768
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center